parainfluenza
viru
formerli
simian
viru
member
rubulaviru
genu
famili
paramyxovirida
includ
mani
import
human
anim
pathogen
respiratori
syncyti
viru
rsv
measl
viru
newcastl
diseas
viru
ndv
nipah
viru
niv
sendai
viru
rinderpest
viru
canin
distemp
viru
although
origin
unclear
thought
abl
infect
human
anim
includ
dog
pig
cat
hamster
guinea
pig
cattl
parainfluenza
viru
first
isol
contamin
simian
cell
thu
name
simian
viru
howev
suffici
evid
subsequ
studi
indic
simian
viru
therefor
viru
subsequ
renam
intern
committe
taxonomi
virus
notabl
renam
mammalian
rubulaviru
name
use
parainfluenza
viru
associ
human
diseas
diseas
multipl
sclerosi
common
cold
subsequ
studi
unabl
confirm
etiolog
agent
parainfluenza
viru
thought
contribut
upper
respiratori
infect
dog
common
compon
vaccin
design
prevent
canin
infecti
respiratori
diseas
also
known
kennel
cough
infect
dog
lead
respiratori
ill
indic
alon
pathogen
veterinari
vaccin
contain
live
use
dog
least
year
without
safeti
suggest
safe
first
rescu
rabi
viru
rabv
clone
cdna
mark
major
mileston
field
nonseg
rna
viru
nnsv
sinc
revers
genet
system
nnsv
develop
becom
power
tool
basic
viru
research
translat
research
includ
use
vaccin
vector
prevent
infecti
diseas
deliveri
vector
gene
therapi
past
decad
nnsv
member
includ
sendai
viru
vesicular
stomat
viru
ndv
rabv
extens
explor
parainfluenza
viru
also
emerg
novel
attract
vector
vaccin
studi
parainfluenza
viru
nnsv
member
infect
host
respiratori
epithelium
make
attract
vector
develop
vaccin
induc
protect
mucos
immun
respons
far
number
vaccin
candid
success
protect
viral
bacteri
infect
multipl
anim
model
suggest
vector
highli
worthi
explor
field
vaccin
research
first
review
vaccin
human
anim
infecti
diseas
tabl
along
discuss
advantag
vaccin
vector
platform
aid
futur
vaccin
design
acceler
progress
vaccin
clinic
trial
parainfluenza
viru
nonseg
genom
consist
singl
strand
rna
nucleotid
nt
length
total
length
viru
genom
multipl
encapsid
n
protein
provid
protect
nucleas
digest
genom
flank
sequenc
includ
nonoverlap
gene
order
encod
nucleocapsid
protein
np
v
protein
v
phosphoprotein
p
matrix
protein
fusion
protein
f
small
hydrophob
protein
sh
hn
rna
polymeras
larg
protein
l
v
encod
singl
gene
vp
deriv
unedit
rna
p
gener
rna
edit
vp
gene
insert
two
nontempl
guanin
nucleotid
transcript
result
frame
shift
rna
polymeras
consist
two
protein
p
l
l
protein
respons
major
enzymat
activ
involv
viral
rna
replic
transcript
well
addit
cap
structur
poli
parainfluenza
viru
rna
genom
includ
genom
antigenom
encapsid
np
form
helic
ribonucleoprotein
essenti
viru
assembl
bud
genom
contain
noncod
region
gene
junction
gene
rang
size
approxim
nt
noncod
region
involv
gene
end
ge
transcript
signal
intergen
region
gene
start
gs
signal
ge
gs
signal
control
transcript
termin
reiniti
upstream
downstream
gene
polar
mechan
transcript
result
gradient
mrna
abund
highest
end
genom
decreas
toward
end
follow
order
np
vp
f
sh
hn
l
figur
revers
genet
system
rescu
first
establish
viru
rescu
clone
cdna
contain
full
genom
sequenc
orient
flank
promot
hepat
delta
viru
ribozym
rescu
cell
infect
recombin
vaccinia
viru
express
rna
polymeras
transfect
molecular
clone
along
helper
plasmid
encod
np
p
l
gene
viral
rna
synthes
rna
polymeras
encapsid
np
associ
polymeras
complex
compos
p
l
polymeras
complex
transcrib
replic
genom
progeni
virion
produc
rescu
filter
filter
remov
vaccinia
viru
avoid
cell
damag
caus
vaccinia
viru
infect
biosafeti
purpos
altern
rescu
approach
develop
requir
vaccinia
viru
exampl
babi
hamster
kidney
fibroblast
bhk
cell
line
constitut
express
rna
polymeras
use
place
anoth
approach
prefer
use
laboratori
involv
construct
eukaryot
plasmid
express
rna
polymeras
cotransfect
infecti
clone
plasmid
np
p
plasmid
figur
method
ad
benefit
enabl
viru
rescu
multipl
cell
line
flexibl
import
special
requir
viru
stock
product
recombin
virus
rescu
effici
approach
directli
use
research
without
need
remov
vaccinia
viru
rescu
recombin
virus
express
foreign
gene
use
revers
genet
system
critic
insert
foreign
gene
genom
strateg
gener
foreign
gene
insert
noncod
region
addit
transcript
unit
includ
gs
sequenc
foreign
gene
ge
sequenc
laboratori
foreign
gene
routin
insert
end
upstream
gene
gene
junction
sequenc
use
strategi
one
need
artifici
insert
gene
junction
sequenc
end
upstream
gene
foreign
gene
transcript
origin
upstream
downstream
gene
remain
activ
foreign
gene
transcript
unit
function
gene
express
mention
previous
genom
sequenc
recombin
genom
adher
rule
six
enabl
proper
genom
encapsid
therebi
maintain
integr
genom
effici
viru
replic
insert
site
anoth
import
factor
consid
impact
foreign
gene
express
level
viral
replic
effici
principl
foreign
gene
abundantli
express
closer
end
viru
genom
case
ndv
express
vector
insert
foreign
gene
pm
intergen
site
viru
genom
prefer
optim
foreign
gene
ideal
insert
site
foreign
gene
balanc
viru
replic
foreign
gene
express
contain
optim
arrang
gene
junction
sequenc
foreign
gene
parainfluenza
viru
good
candid
develop
viral
vector
vaccin
safeti
genom
stabil
abil
grow
multipl
cell
line
accommod
foreign
gene
variou
size
parainfluenza
viru
dna
phase
life
cycl
therebi
avoid
risk
genet
modif
host
cell
dna
recombin
insert
furthermor
although
infect
mani
anim
speci
thu
far
suffici
evid
indic
caus
diseas
anim
speci
even
human
therefor
thought
rel
safe
vaccin
vector
advantag
viru
vector
develop
rabv
vesicular
stomat
viru
encount
issu
viru
revers
residu
virul
etc
genom
harbor
foreign
gene
rel
stabl
issu
genom
recombin
loss
foreign
gene
frequent
happen
rna
viru
remark
maintain
express
gfp
gene
gener
cell
addit
stabli
retain
foreign
gene
vitro
vivo
passag
parainfluenza
viru
infect
wide
rang
cell
type
includ
primari
human
cell
establish
human
cell
line
parainfluenza
viru
also
infect
larg
number
mammal
without
caus
vero
cell
cell
line
vaccin
product
ideal
cell
substrat
propag
viral
titer
parainfluenza
viru
abil
grow
high
titer
make
amen
develop
vaccin
furthermor
replic
respiratori
tract
anim
offer
attract
rout
deliv
vaccin
mucos
immun
import
protect
pathogen
infect
parainfluenza
viru
virion
highli
pleomorph
size
rang
nm
diamet
figur
structur
versatil
allow
genom
accommod
foreign
gene
variou
size
advantag
use
vaccin
vector
maximum
size
gene
insert
unclear
studi
shown
insert
gene
nt
length
significantli
affect
growth
virion
integr
unpublish
data
thu
size
genom
may
tightli
restrict
virion
structur
first
foreign
gene
insert
genom
green
fluoresc
protein
gfp
parainfluenza
viru
express
gfp
replic
similar
titer
viru
cell
line
without
inhibit
viru
growth
instabl
gfp
gene
insert
first
studi
confirm
could
use
foreign
gene
express
feasibl
use
recombin
vaccin
vector
sinc
test
first
exampl
express
ha
gene
influenza
subtyp
viru
gene
junction
hn
l
gene
interestingli
ha
express
cell
also
incorpor
virion
infect
replic
mice
caus
clinic
sign
diseas
weight
loss
compar
mice
singl
dose
intranas
vaccin
provid
protect
immun
mice
influenza
viru
infect
first
studi
demonstr
could
use
vector
provid
protect
immun
influenza
viru
infect
influenza
viru
ha
protein
incorpor
particl
thought
enhanc
immun
respons
function
particl
deliv
envelop
protein
viral
pathogen
may
present
surfac
viru
particl
enhanc
immun
respons
confirm
studi
vaccin
influenza
viru
initi
studi
show
intranas
vaccin
success
protect
homolog
influenza
viru
challeng
challeng
viru
suffici
virul
caus
death
mice
subsequ
studi
sought
investig
efficaci
influenza
vaccin
infect
virul
strain
influenza
viru
live
express
ha
influenza
viru
test
highli
pathogen
avian
influenza
hpai
challeng
efficaci
singl
intranas
dose
protect
mice
challeng
investig
impact
foreign
gene
insert
site
within
genom
efficaci
vaccin
candid
ha
insert
differ
gene
junction
genom
extra
express
cassett
insert
ha
sh
hn
induc
best
protect
antibodi
respons
robust
cellular
immun
respons
compar
junction
site
determin
insert
foreign
gene
genom
valuabl
vaccin
research
case
inject
vaccin
prefer
mass
vaccin
veterinari
field
therefor
anoth
studi
sought
investig
efficaci
influenza
vaccin
altern
immun
rout
singl
intramuscular
inocul
rapidli
gener
neutral
antibodi
respons
provid
incomplet
protect
hpai
cell
respons
robustli
prime
intramuscularli
vaccin
mice
inactiv
influenza
vaccin
induc
poor
cellular
immun
respons
find
demonstr
potenti
use
intramuscular
vaccin
protect
human
anim
hpai
infect
univers
influenza
viru
vaccin
urgent
need
provid
emerg
diverg
strain
influenza
viru
influenza
viru
np
intern
structur
protein
highli
conserv
among
strain
influenza
virus
therefor
explor
promis
antigen
develop
univers
influenza
viru
recombin
express
np
hpai
strain
examin
protect
efficaci
homolog
hpai
viru
challeng
heterosubtyp
singl
dose
provid
complet
protect
lethal
influenza
viru
strain
challeng
weight
loss
observ
immun
prevent
influenza
viru
infect
lung
mice
even
still
superior
vaccinia
viru
vv
adenoviru
express
np
studi
group
fail
provid
protect
homolog
viru
provid
protect
lethal
challeng
weight
loss
although
result
demonstr
potenti
univers
influenza
viru
vaccin
efficaci
may
enhanc
use
regimen
increas
inocul
dose
combin
influenza
viru
antigen
sinc
influenza
viru
infect
found
bird
peopl
chines
mainland
although
viru
low
virul
poultri
fatal
human
urgent
need
develop
vaccin
human
use
virus
express
ha
np
gene
test
immunogen
efficaci
influenza
viru
challeng
mice
guinea
mice
surviv
lethal
challeng
ha
antibodi
titer
found
poor
correl
protect
combin
complet
block
viru
transmiss
alon
protect
guinea
pig
infect
suggest
cellular
immun
respons
play
major
role
protect
viru
challeng
although
studi
warrant
research
use
differ
anim
model
confirm
result
demonstr
promis
new
platform
develop
vaccin
influenza
viru
neuraminidas
na
also
explor
influenza
vaccin
antigen
studi
shown
antigen
variat
na
lower
ha
na
antibodi
provid
broader
rang
protect
immun
therefor
virus
express
na
avian
pandem
influenza
virus
investig
result
show
confer
protect
homolog
heterolog
influenza
viru
challeng
case
express
na
two
vaccin
dose
even
confer
steril
immun
infect
mice
vaccin
also
abl
reduc
clinic
sign
diseas
influenza
viru
shed
ferret
studi
indic
express
na
potenti
exploit
univers
influenza
vaccin
broader
spectrum
protect
immun
divers
influenza
viru
strain
newli
emerg
influenza
virus
combin
vaccin
express
na
ha
np
influenza
viru
worthi
investig
studi
conduct
enhanc
potenti
vaccin
vector
viral
infect
interfer
apoptot
pathway
may
affect
antigen
present
result
alter
immun
respons
sinc
sh
v
protein
block
hypothes
virus
lack
sh
v
gene
may
present
vaccin
antigen
effici
wild
type
virus
lack
sh
gene
conserv
region
v
protein
engin
express
ha
compar
wild
type
induc
strongest
antibodi
respons
demonstr
superior
protect
lethal
challeng
mice
result
suggest
modif
abil
antagon
host
cell
apoptosi
may
enhanc
immunogen
foreign
antigen
current
rabi
vaccin
immunoglobulin
therapi
avail
human
anim
rabv
infect
prophylaxi
treatment
howev
expens
make
vaccin
treatment
inaccess
famili
especi
develop
countri
altern
approach
includ
vaccin
stray
dog
wild
anim
aim
reduc
public
health
risk
human
domest
anim
address
issu
recombin
encod
g
gene
rabv
gener
evalu
potenti
rabi
vaccin
induc
protect
immun
respons
via
intranas
intramuscular
oral
immun
robust
rabv
challeng
first
demonstr
efficaci
oral
immun
rabi
vaccin
align
vaccin
strategi
protect
stray
dog
wild
anim
rabi
furthermor
sinc
live
use
extens
dog
compon
kennel
cough
vaccin
feasibl
replac
routin
vaccin
schedul
dog
studi
perform
investig
efficaci
therapi
rabv
infect
mice
intramuscularli
infect
rabv
commonli
reach
anim
brain
day
day
rabv
infect
mice
inject
intracerebr
attenu
rabv
express
fifti
percent
mice
surviv
even
onset
clinic
sign
day
infect
effect
treat
mice
improv
efficaci
combin
therapi
antibodi
worthi
investig
unlik
attenu
rabv
vaccin
neutral
antibodi
attenu
rabv
vaccin
also
safeti
concern
inject
human
brain
respiratori
syncyti
viru
one
lead
caus
respiratori
ill
result
mortal
morbid
young
children
immunocompromis
individu
senior
citizen
thu
far
licens
rsv
vaccin
safe
efficaci
rsv
vaccin
remain
unmet
need
two
vaccin
express
rsv
glycoprotein
f
g
evalu
anim
model
immunogen
efficaci
protect
rsv
first
examin
mice
test
found
serum
neutral
antibodi
gener
mice
mice
despit
reduc
viral
burden
found
lung
mice
presum
rsv
antibodi
protect
independ
convent
neutral
activ
vitro
work
demonstr
immun
elicit
protect
immun
rsv
challeng
mice
evalu
inocul
relev
preclin
anim
cotton
rat
elicit
serum
antibodi
confer
complet
protect
lung
rsv
challeng
african
green
monkey
confer
greatest
reduct
rsv
titer
respiratori
tract
rel
less
efficaci
vaccin
also
abl
boost
rsv
neutral
antibodi
respons
african
green
monkey
prior
exposur
rsv
studi
demonstr
promis
vaccin
vector
person
pediatr
elderli
rsv
infect
superior
rsv
vaccin
candid
recent
addit
work
publish
improv
vaccin
candid
contain
vector
antigen
insert
gene
junction
use
replac
sh
base
previou
find
vector
modif
could
increas
vaccin
efficaci
parainfluenza
viru
also
engin
express
stabil
insert
site
potenti
gener
potent
neutral
respons
rsv
conform
although
vaccin
candid
stimul
strong
host
immun
respons
rsv
burden
upper
lower
respiratori
tract
reduc
gener
higher
level
neutral
antibodi
find
suggest
import
consid
design
highli
efficaci
recombin
rsv
vaccin
also
demonstr
rsv
vaccin
could
administ
subcutan
provid
favor
rout
vaccin
infant
may
suffer
nasal
congest
due
intranas
inocul
parainfluenza
viru
also
engin
express
bacteri
antigen
vaccin
develop
mycobacterium
tuberculosi
etiolog
agent
tuberculosi
tb
one
main
caus
disabl
death
worldwid
bcg
bacil
attenu
strain
mycobacterium
bovi
avail
tb
vaccin
despit
question
regard
variabl
effect
pulmonari
tb
adult
parainfluenza
viru
use
express
mycobacterium
tuberculosi
antigen
immunogen
protect
efficaci
evalu
mous
aerosol
infect
effect
reduc
bacteri
burden
lung
could
also
boost
efficaci
bcg
primari
immun
improv
result
much
reduct
bacteri
load
first
time
vaccin
shown
boost
vaccin
efficaci
heterolog
regimen
suggest
tb
vaccin
promis
candid
research
effort
use
virus
deliveri
vector
vaccin
fraught
difficulti
field
human
veterinari
medicin
human
anim
preexist
immun
especi
neutral
antibodi
viral
vector
theoret
inhibit
viru
entri
host
cell
therebi
reduc
dose
antigen
vector
determin
presenc
preexist
immun
detriment
efficaci
vaccin
dog
prior
exposur
inocul
efficaci
ha
influenza
viru
subtyp
dog
seroconvert
week
postinocul
hemaggluitin
inhibit
antibodi
titer
viru
greater
consid
protect
immunolog
standard
week
postinocul
result
indic
prior
exposur
prevent
vaccin
gener
protect
immun
result
consist
previou
find
antibodi
prevent
infect
exposur
human
popul
also
investig
neutral
antibodi
detect
human
serum
sampl
titer
lower
dog
prior
exposur
result
suggest
vaccin
may
abl
overcom
preexist
immun
induc
immunogen
protect
immun
respons
pathogen
infect
human
safeti
alway
critic
concern
vaccin
research
develop
previous
mention
highli
stabl
genom
replic
cytoplasm
elimin
possibl
viral
genom
integr
dna
host
cell
parainfluenza
viru
consid
nonpathogen
low
virul
multipl
anim
speci
human
therefor
concern
virul
revers
residu
virul
use
vaccin
vector
unlik
pathogen
furthermor
unlik
rna
virus
influenza
evid
genet
recombin
occur
virus
indic
vector
recombin
virus
creat
mutant
novel
pathogen
featur
concern
express
foreign
viral
envelop
protein
use
vaccin
vector
may
expand
tropism
pathogen
viral
vector
thu
far
evid
indic
occur
vaccin
research
exampl
vaccin
express
influenza
viru
ha
protein
test
nude
mice
address
issu
potenti
enhanc
sign
ill
weight
loss
observ
mice
infect
consist
find
recombin
ferret
mice
display
clinic
sign
diseas
discern
ideal
vaccin
elicit
robust
b
protect
humor
immun
respons
also
gener
cell
cell
previous
discuss
vector
abl
induc
strong
humor
immun
protect
varieti
vaccin
target
induct
cellular
immun
also
critic
protect
pathogen
induct
cellular
immun
investig
depth
abil
induc
cellular
immun
respons
test
use
express
model
antigen
chicken
ovalbumin
experi
mice
inocul
intranas
respons
vaccin
elicit
strong
cytotox
lymphocyt
ctl
respons
high
avid
ovalbumin
result
suggest
good
vaccin
vector
viral
antigen
sinc
high
avid
ctl
respons
optim
viru
sinc
replic
primarili
occur
respiratori
tract
qualiti
make
attract
vaccin
vector
gener
high
avid
ctl
respons
respiratori
mucos
pathogen
infect
tremend
advanc
viral
vaccin
vector
develop
made
past
decad
advanc
reli
improv
understand
viral
biolog
updat
insight
reciproc
interact
virus
host
immun
current
viral
vector
vaccin
remain
one
best
strategi
induct
robust
humor
cellular
immun
human
anim
infecti
diseas
parainfluenza
viru
becom
attract
vector
field
vaccin
research
particularli
develop
vaccin
requir
induct
protect
mucos
immun
respons
use
vector
appear
pose
major
risk
anim
human
health
concern
virul
revers
residu
virul
viru
recombin
futur
design
immun
strategi
vector
optim
induc
potent
complet
protect
immun
anim
human
reduc
diseas
defend
infecti
pathogen
author
compet
interest
